UBS Group
HRTX icon

UBS Group’s Heron Therapeutics HRTX Stock Holding History

UBS Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-700
Closed -$17K – 8447
2015
Q3 		$17K Sell
700
-15,000
-96% -$500K ﹤0.01% 6849
2015
Q2 		$489K Buy
+15,700
New +$295K ﹤0.01% 4152

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

UBS Group's HRTX Position: Q1 2026 in Review

UBS Group increased its Heron Therapeutics (HRTX) stake by 9.3% in Q1 2026, buying an estimated $225K and bringing the position to 2,285,883 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #5056.

UBS Group first reported a position in HRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $9.38M in Q4 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • UBS Group held 2,285,883 shares of Heron Therapeutics worth $1.83M as of Q1 2026.
  • UBS Group bought 194,214 Heron Therapeutics shares in Q1 2026, an estimated $225K.
  • Heron Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5056 holding.
  • UBS Group first reported a position in Heron Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Heron Therapeutics position peaked at $9.38M in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.